Arcus Biosciences Announces New Employment Inducement Grant

August 4, 2020 |

2 min read

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on July 7, 2020, the company made an inducement grant to Robert C. Goeltz II, the newly-appointed Chief Financial Officer of Arcus

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on July 7, 2020, the company made an inducement grant to Robert C. Goeltz II, the newly-appointed Chief Financial Officer of Arcus. The Compensation Committee of the Company’s Board of Directors granted Mr. Goeltz an option to purchase a total of 250,000 shares of the Company’s common stock at an exercise price per share of $21.06, which was the closing price on August 3, 2020. The stock option was granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to create highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: AB928, the first and only dual A_2a/A_2badenosine receptor antagonist in the clinic, is being evaluated in multiple Phase 1b/2 studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic, triple-negative breast and renal cell cancers. AB680, the first small-molecule CD73 inhibitor in the clinic, is in Phase 1 development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. AB154, an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-high metastatic non-small cell lung cancer evaluating zimberelimab monotherapy, AB154 with zimberelimab and AB154 plus AB928 with zimberelimab. Zimberelimab (AB122), Arcus’s anti-PD-1 monoclonal antibody, is also being evaluated in a Phase 1b study as monotherapy for cancers with no approved anti-PD-1 treatment options, and in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005944/en/

Contacts

Katherine Bock
(510) 694-6231
kbock@arcusbio.com

Source: Arcus Biosciences

View this news release online at:
http://www.businesswire.com/news/home/20200804005944/en

People

Arcus Biosciences, Inc.